APA (7th ed.) Citation

Middleton, G., Palmer, D. H., Greenhalf, W., Ghaneh, P., Jackson, R., Cox, T., . . . Neoptolemos, J. P. (2017). Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): A prospective, randomised, double-blind, multicentre phase 2 trial. Elsevier.

Chicago Style (17th ed.) Citation

Middleton, Gary, et al. Vandetanib Plus Gemcitabine Versus Placebo Plus gemcitabine in Locally Advanced or Metastatic Pancreatic carcinoma (ViP): A Prospective, Randomised, Double-blind, multicentre Phase 2 Trial. Elsevier, 2017.

MLA (9th ed.) Citation

Middleton, Gary, et al. Vandetanib Plus Gemcitabine Versus Placebo Plus gemcitabine in Locally Advanced or Metastatic Pancreatic carcinoma (ViP): A Prospective, Randomised, Double-blind, multicentre Phase 2 Trial. Elsevier, 2017.